Philogen SpA (IT:PHIL)
:PHIL
Top Page
Philogen SpA
(PHIL)
Select Model
Select Model
Rating:74Outperform
Price Target:
€26.00
▲(12.07% Upside)
Action:ReiteratedDate:10/15/25
Philogen SpA's overall stock score of 74 is driven primarily by strong financial performance (score: 80, weight: 0.5), reflecting high profitability, low leverage, and solid cash generation, though tempered by moderate growth. Technical analysis (score: 65, weight: 0.3) indicates a mild bullish trend but neutral momentum, while valuation (score: 70, weight: 0.2) suggests fair pricing with a reasonable P/E ratio. The score reflects a positive outlook with caution due to growth and momentum concerns.
Positive Factors
Revenue Growth
Consistent revenue growth indicates expanding market reach and effective product adoption, supporting long-term business sustainability.
Negative Factors
Free Cash Flow Growth
Negative free cash flow growth may limit the company's ability to fund new projects and return value to shareholders, potentially impacting long-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates expanding market reach and effective product adoption, supporting long-term business sustainability.
Read all positive factors
Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€599.48M
Dividend YieldN/A
Average Volume (3M)19.28K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue Growth3346.54%
EPS GrowthN/A
CountryIT
Employees174
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)6.07
Shares Outstanding29,242,860
10 Day Avg. Volume19,753
30 Day Avg. Volume19,281
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.67
Price to Sales (P/S)10.62
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.00Price Target Upside-22.41% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.76
Revenue Forecast (FY)€6.20M
Philogen SpA Business Overview & Revenue Model
Company Description
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma a...
How the Company Makes Money
Philogen generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, which provide funding for research and development initiatives in exchange for rights to develop and commercialize its therapeuti...
Philogen SpA Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.86M | 74.00M | 23.13M | 23.71M | 2.50M | 4.78M |
| Gross Profit | 43.76M | 54.42M | 5.67M | 10.53M | -8.14M | -5.05M |
| EBITDA | 43.70M | 44.75M | -2.05M | -1.17M | -12.98M | -10.53M |
| Net Income | 45.91M | 45.29M | -6.16M | -5.38M | -15.72M | -13.29M |
Balance Sheet | ||||||
| Total Assets | 159.35M | 168.45M | 119.27M | 125.83M | 132.75M | 85.47M |
| Cash, Cash Equivalents and Short-Term Investments | 100.02M | 113.73M | 75.34M | 86.20M | 101.68M | 61.94M |
| Total Debt | 11.50M | 11.51M | 14.91M | 15.76M | 16.49M | 17.70M |
| Total Liabilities | 33.54M | 29.80M | 28.68M | 27.91M | 27.67M | 29.80M |
| Stockholders Equity | 125.81M | 138.66M | 90.59M | 97.92M | 105.09M | 55.67M |
Cash Flow | ||||||
| Free Cash Flow | 37.15M | 38.67M | -10.37M | -9.15M | -25.85M | -16.81M |
| Operating Cash Flow | 39.55M | 40.84M | -4.82M | -4.94M | -19.03M | -13.16M |
| Investing Cash Flow | -36.03M | -22.28M | 159.00K | 24.20M | -47.77M | 17.77M |
| Financing Cash Flow | -4.80M | -3.78M | -4.17M | -3.78M | 63.05M | 3.79M |
Philogen SpA Technical Analysis
Negative
23.20
Price Trends
21.77
Negative
22.35
Negative
22.66
Negative
Market Momentum
-0.07
Positive
34.57
Neutral
16.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Negative. The current price of 23.2 is above the 20-day moving average (MA) of 22.44, above the 50-day MA of 21.77, and above the 200-day MA of 22.66, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.57 is Neutral, neither overbought nor oversold. The STOCH value of 16.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHIL.
Philogen SpA Peers Comparison
UnderperformOutperform
Sector (51)
IT:PHIL
Philogen SpA
20.00
0.30
1.52%
IT:PHN
PharmaNutra SpA
78.60
30.54
63.55%
IT:GHC
Garofalo Health Care S.P.A.
4.68
-0.36
-7.07%
IT:ARBS
Arterra Bioscience SpA
3.04
1.02
50.50%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.09
-0.01
-0.91%
IT:SVS
Svas Biosana S.p.A.
8.58
1.60
22.92%
Philogen SpA Corporate Events
Philogen Increases Treasury Stock with New Tranche of Share Buybacks
Feb 2, 2026
Philogen S.p.A. has disclosed an update on its ongoing share buyback program, reporting the repurchase of 949 own shares between 26 and 30 January 2026 on Euronext Milan at an average price of €21.3147 per share, for a total outlay of €...
Philogen Updates on Share Buyback Program
Dec 9, 2025
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 4,000 shares from December 1 to December 5, 2025, at an average price of Euro 22.9250 per share, totaling Euro 91,700. This buyback is part of a broade...
Philogen S.p.A. Reports Strong Financial Position and Advances in Clinical Trials
Nov 11, 2025
Philogen S.p.A. has reported a positive net financial position of 369,164 thousand euros for the third quarter of 2025, marking a significant increase from the previous quarter. The company is advancing its clinical trials for Nidlegy™ and F...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.